Johnson & Johnson stock outperforms competitors despite losses on the day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Johnson & Johnson (JNJ) And Encourages Investors to Reach Out
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf ...
Hold Recommendation for Johnson & Johnson Amid Promising Drug Trials and Regulatory Challenges
Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) and keeping the price ...
Johnson & Johnson Gets FDA Priority Review of Nipocalimab in Generalized Myasthenia Gravis
Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia gravis.